Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243)
Based on 1 Customer Validation
Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) is a mouse-derived IgG2a κ type antibody inhibitor, targeting to monkey/human MHC class II. Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) can inhibits tumor cells proliferation and induce apoptosis. Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) increases cellular reactive oxygen species (ROS) and loss of mitochondrial membrane potential in human endothelial cells. Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) can be used for the researches of cancer and infection, such as lymphoma.
For research use only. We do not sell to patients.
- Purity : 95.00%
- Molecular Weight:150 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
Isotype
Mouse IgG2a kappa
Recommend Isotype Controls
Species Reactivity
Human/Monkey
IC50 & Target
MHC class II
In Vitro
Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) (3 h) induces significantly cell lysis in Raji, Ramos and Namalwa cells[1].
Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) (1-100 nM, 48-72 h) inhibits proliferation of Raji and Daudi cell lines[1].
Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) (4-24 h) induces apoptosis in Daudi lymhoma cells[1].
Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) (48 h) induces activation of caspase-3 and AKT in a panel of lymphoma cell lines[1].
Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) (5 µg/mL, 3 h) induces necrotic cell death in human endothelial cells and reorganization of the cytoskeleton is involved[2].
Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) (5 µg/mL, 1 h) increases cellular ROS and loss of mitochondrial membrane potential in human endothelial cells[2].
Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) (5 µg/mL, 3 h) induces lysosomal activation, LMP, and rupture in endothelial cells[2].
Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) (3-6 days) selectively suppresses the proliferation of established Epstein-Barr virus-transformed lymphoblastoid cell lines and Epstein-Barr virus-infected B cells[3].
Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) (20 h) down-regulates the expression of CD23 and CD20 antigens in lymphoblastoid cell lines[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Severe combined immunodeficiency (SCID) CB-17 mice were given injections of Raji cells[1]
-
Dosage:10, 30, 100 and 300 μg
-
Administration:Intraperitoneally injection, twice a week for 4 weeks
-
Result:Prolonged survival times.
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Product Image
Application
in vitro blocking of MHC class II HLA-DRHLA class II binding assayin vitro MHC class II HLA-DR expre
Chemical Information
-
Appearance Liquid
-
Molecular Weight 150 kDa
-
Color Colorless to light yellow
-
SMILES
[Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243)]
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (262 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Goulet DR, Atkins WM. Considerations for the Design of Antibody-Based Therapeutics. J Pharm Sci. 2020 Jan;109(1):74-103. [Content Brief]
[2]. Stein R, et al. Characterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximab. Blood. 2006 Oct 15;108(8):2736-44. [Content Brief]
[3]. Aljabri A, et al. HLA class II antibodies induce necrotic cell death in human endothelial cells via a lysosomal membrane permeabilization-mediated pathway. Cell Death Dis. 2019 Mar 8;10(3):235. [Content Brief]
[4]. Kabelitz D, et al. Growth inhibition of Epstein-Barr virus-transformed B cells by anti-HLA-DR antibody L243: possible relationship to L243-induced down-regulation of CD23 antigen expression. Cell Immunol. 1989 Apr 15;120(1):21-30. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) Related Classifications
HY-P990189 Related Classifications
Powered by Bioz